NOT-AI-02-030: PRODUCTION OF BOTULINUM ANTI-TOXIN IMMUNOGLOBULIN

Department of Health
and Human Services (HHS)

NIH... Turning Discovery Into Health^®



PRODUCTION OF BOTULINUM ANTI-TOXIN IMMUNOGLOBULIN 

Release Date:  June 13, 2002

NOTICE:  NOT-AI-02-030 

National Institute of Allergy and Infectious Diseases (NIAID)
 (http://www.niaid.nih.gov)

Receipt Date for Letter of Interest: July 12, 2002

The National Institute of Allergy and Infectious Diseases (NIAID) is interested 
in supporting the development and licensure of botulinum anti-toxin 
immunoglobulin as a part of our Biodefense program.

NIAID is interested in receiving letters from organizations that have the needed 
development and production capabilities. Interested organizations should submit 
a letter of interest that contains a detailed description of a potential 
development, production and marketing plan, as well as their R&D capabilities 
and interest. The letter of interest along with any supporting documentation 
shall not exceed 10 pages. Letters of interest will be kept confidential and 
will help in determining the need for an RFP to support further development, 
testing, and licensure of these products, and in assembling a potential source 
list for distribution if an RFP is issued.

INQUIRIES

Submit your response to the address listed below:

Barbara A. Shadrick
Senior Contracting Officer
Contract Management Branch, DEA
National Institute of Allergy and Infectious Diseases, NIH
6700-B Rockledge Drive, Room 2230, MSC 7612
Bethesda, MD  20892-7612 
Phone:  301-496-7288
Fax:  301-480-5253 or 301-402-0972
E-Mail:  [email protected]

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices